Biocryst Pharmaceuticals (BCRX) EBIT (2010 - 2026)

Biocryst Pharmaceuticals (BCRX) has reported EBIT for 17 consecutive years, with $98.5 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, EBIT rose 230.57% year-over-year to $98.5 million; the trailing twelve-month figure through Jun 2026 stood at -$313.2 million (down 677.81% YoY), and the FY2025 full-year result was $341.0 million, up 13508.93% from the prior year.
• EBIT improved to $98.5 million in Q2 2026 per BCRX's latest filing, from -$701.6 million in the prior quarter.
• Across five years, EBIT topped out at $260.4 million in Q4 2025 and bottomed at -$701.6 million in Q1 2026.
• Historically, EBIT has averaged -$28.7 million across 5 years, with a median of -$13.2 million in 2023.
• The sharpest annual moves came in 2025 and 2026: EBIT soared 5876.06% in 2025, then plunged 3405.22% in 2026.
• Over 5 years, EBIT stood at -$46.3 million in 2022, then grew by 7.86% to -$42.7 million in 2023, then soared by 89.44% to -$4.5 million in 2024, then jumped by 5876.06% to $260.4 million in 2025, then tumbled by 62.18% to $98.5 million in 2026.
• According to Business Quant data, EBIT over the past three periods registered $98.5 million, -$701.6 million, and $260.4 million for Q2 2026, Q1 2026, and Q4 2025 respectively.